- Home
- CAPR vs TPVG Comparison
CAPR vs TPVG Comparison
Compare CAPR & TPVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- TPVG
- Stock Information
- Founded
- CAPR 2005
- TPVG 2013
- Country
- CAPR United States
- TPVG United States
- Employees
- CAPR N/A
- TPVG N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- TPVG Other Consumer Services
- Sector
- CAPR Health Care
- TPVG Consumer Discretionary
- Exchange
- CAPR Nasdaq
- TPVG Nasdaq
- Market Cap
- CAPR 332.5M
- TPVG 316.4M
- IPO Year
- CAPR N/A
- TPVG N/A
- Fundamental
- Price
- CAPR $17.79
- TPVG $8.06
- Analyst Decision
- CAPR Strong Buy
- TPVG Hold
- Analyst Count
- CAPR 7
- TPVG 6
- Target Price
- CAPR $39.29
- TPVG $7.81
- AVG Volume (30 Days)
- CAPR 1.1M
- TPVG 304.3K
- Earning Date
- CAPR 11-13-2024
- TPVG 11-06-2024
- Dividend Yield
- CAPR N/A
- TPVG 18.68%
- EPS Growth
- CAPR N/A
- TPVG N/A
- EPS
- CAPR N/A
- TPVG 0.27
- Revenue
- CAPR $23,228,045.00
- TPVG $115,271,000.00
- Revenue This Year
- CAPR N/A
- TPVG N/A
- Revenue Next Year
- CAPR $135.53
- TPVG N/A
- P/E Ratio
- CAPR N/A
- TPVG $29.48
- Revenue Growth
- CAPR 65.33
- TPVG N/A
- 52 Week Low
- CAPR $2.90
- TPVG $6.44
- 52 Week High
- CAPR $23.40
- TPVG $11.58
- Technical
- Relative Strength Index (RSI)
- CAPR 47.77
- TPVG 73.39
- Support Level
- CAPR $17.21
- TPVG $7.83
- Resistance Level
- CAPR $19.47
- TPVG $8.02
- Average True Range (ATR)
- CAPR 1.64
- TPVG 0.21
- MACD
- CAPR -0.38
- TPVG 0.08
- Stochastic Oscillator
- CAPR 28.33
- TPVG 99.08
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.